Sangamo plunges 38% after Pfizer ends agreement on hemophilia A gene therapy
Hawkinsight
2024-12-31 09:07:03
1.96W
pictafolio
- Sangamo Therapeutics (NASDAQ:SGMO) is down ~38% in after-hours trading Monday after announcing that Pfizer (NYSE:PFE) is returning the development and commercialization rights to hemophilia A gene therapy candidate giroctocogene fitelparvovec.
- Sangamo said Pfizer has decided not to pursue commercialization of
Disclaimer: The views in this article are from the original Creator and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.
